Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin

Autor: Ted Gooley, Barry E. Storer, Frederick R. Appelbaum, Mohamed L. Sorror, Albert C. Yeh, Jason P. Cooper, Kris Doney, Paul O'Donnell, Paul J. Martin, Jeannine S. McCune, H. Joachim Deeg, Gary Schoch, Mary E.D. Flowers, C. McFarland
Rok vydání: 2021
Předmět:
Zdroj: Bone Marrow Transplant
ISSN: 1476-5365
0268-3369
DOI: 10.1038/s41409-021-01518-0
Popis: We evaluated long-term outcome in 40 patients with MDS or AML, transplanted from related or unrelated donors following conditioning with targeted busulfan (Bu, over 4 days), fludarabine (Flu, 120 [n=23] or 250 [n=17] mg/m(2)) and thymoglobulin (THY). Compared to 95 patients conditioned with Bu/Cyclophosphamide (Cy) without THY, BuFluTHY-conditioned patients had lower rates of chronic graft-vs.-host disease (GVHD). Adjusted hazard ratios (HR) for BuFlu(120)THY and BuFlu(250)THY-conditioned patients were 1.60 (95% confidence interval (CI) 0.66 to 3.86) and 1.87 (0.68 to 5.11), respectively, for relapse; 0.77 (0.30 to 1.99) and 1.32 (0.54 to 3.23) for non-relapse mortality; 0.81 (0.42 to 1.57) and 1.38 (0.72 to 2.57) for overall mortality; and 0.78 (0.30 to 2.05) and 1.62 (0.63 to 4.41) for relapse or death (failure for relapse-free survival). At one year, 45% of BuFlu(120 or 250)THY conditioned patients had mixed CD3+ chimerism compared to 0% with BuCy (p
Databáze: OpenAIRE
Externí odkaz: